Home
About Us
Management Team
Board of Directors
Scientific Advisory Board
Current Partners
Prospective Partners
What We Do
Cancer Immunotherapy
Pipeline
Technology
Versamune® Platform
Important Characteristics
News
Contact Us
Careers
Open Menu
Home
About Us
Management Team
Board of Directors
Scientific Advisory Board
Current Partners
Prospective Partners
Contact Us
Careers
What We Do
Cancer Immunotherapy
Pipeline
Technology
Versamune® Platform
Important Characteristics
Ushering in a new generation
of cancer immunotherapies
—simpler, safer, and more effective.
Innovative and patented science
We are developing novel targeted immunotherapies that work simultaneously by multiple critical mechanisms
PDS Biotechnology: Versamune®-HPV
The clinical-stage therapy has demonstrated the safety and  potential to treat both early and late stage cancers caused by HPV such as cervical, anal, and head and neck cancers.
Our Team
We have an experienced team focused on developing new treatments for cancer as well as vaccines to protect against disease.
PDS Biotechnology is a biopharmaceutical company developing novel cancer immunotherapies and vaccines for infectious diseases.
PRESS RELEASE: September 19, 2016 BEDU-ADDO TO CHAIR THE THERAPEUTICS/CANCER IMMUNOTHERAPIES SESSION AND PRESENT PHASE I/IIA RESULTS FROM THE PDS0101 PROGRAM AT THE WORLD VACCINE CONGRESS ON OCT 10, 2016
PRESS RELEASE: August 24, 2016 PDS Announces Agreement with FDA on Phase 2 Clinical Path for PDS0101
PRESS RELEASE: April 13, 2016 PDS BIOTECHNOLOGY REPORTS POSITIVE Phase I/IIA STUDY RESULTS FOR PDS0101 IMMUNOTHERAPY FOR HPV-RELATED CANCERS
PRESS RELEASE: February 9, 2016 PDS AND NCI SIGN PHASE 2 CLINICAL CO-DEVELOPMENT AGREEMENT FOR PROSTATE, BREAST AND HPV-CANCERS
PRESS RELEASE: January 19, 2016 IMMUNOTHERAPY COMPANY PDS BIOTECHNOLOGY STRENGTHENS SENIOR MANAGEMENT TEAM, ADDS TWO DRUG DEVELOPMENT EXECUTIVES
CONTACT USPDS Biotechnology Corporation
Commercialization Center for Innovative Technologies (CCIT)
675 US Highway one
North Brunswick, NJ 08902
Tel: 732-640-0145
Fax: 732-640-0144
ABOUT USPDS Biotechnology is a biopharmaceutical company developing novel cancer immunotherapies and vaccines for infectious diseases.
PDS Biotechnology Announces Preliminary DataPDS Biotechnology Corp. announces preliminary data showing that PDS0101, a cancer immunotherapy treatment targeting HPV-16, has generated strong T-cell responses in pre-cervical cancer patients. Currently, pre-cervical cancer is treated by surgical [...]
Read more
©2015 PDS Biotechnology Corporation. All rights reserved.
Scroll